{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:04:00Z","timestamp":1786993440317,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jtct.2024.07.016","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T19:58:40Z","timestamp":1722023920000},"page":"14.e1-14.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Impact of the Type of Tyrosine Kinase Inhibitor (imatinib or dasatinib) Used Before allo-HCT on Outcome of Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia. A Study on Behalf of the Acute Leukemia Working Party of the EBMT"],"prefix":"10.1016","volume":"31","author":[{"given":"Sebastian","family":"Giebel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Labopin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zinaida","family":"Peric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Passweg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5684-9447","authenticated-orcid":false,"given":"Didier","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urpu","family":"Salmenniemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1866-828X","authenticated-orcid":false,"given":"David","family":"Beauvais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Rem\u00e9nyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Chevallier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Mielke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3037-5378","authenticated-orcid":false,"given":"Tobias","family":"Gedde-Dahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan J.","family":"Cornelissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Balsat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2359-131X","authenticated-orcid":false,"given":"Gesine","family":"Bug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Bazarbachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eolia","family":"Brissot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0873-0123","authenticated-orcid":false,"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2024.07.016_bib0001","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1182\/blood-2008-04-149286","article-title":"Patients' age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group","volume":"112","author":"Burmeister","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.07.016_bib0002","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1182\/blood-2006-10-051912","article-title":"Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII\/Eastern Cooperative Oncology Group (ECOG) 2993 trial","volume":"109","author":"Moorman","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.07.016_bib0003","first-page":"868","article-title":"Third International Workshop on chromosomes in leukemia: chromosomal abnormalities and their clinical significance in acute lymphoblastic leukemia","volume":"43","author":"Bloomfield","year":"1983","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtct.2024.07.016_bib0004","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/blood-2003-08-2958","article-title":"Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate","volume":"103","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.07.016_bib0005","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2006-03-011908","article-title":"Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study","volume":"109","author":"de Labarthe","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.07.016_bib0006","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2005-11-4386","article-title":"Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)","volume":"108","author":"Wassmann","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.07.016_bib0007","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2141.2008.07377.x","article-title":"Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy","volume":"143","author":"Yanada","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2024.07.016_bib0008","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3324\/haematol.2009.011221","article-title":"Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial","volume":"95","author":"Ribera","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2024.07.016_bib0009","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1182\/blood-2015-02-627935","article-title":"Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia","volume":"125","author":"Chalandon","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.07.016_bib0010","doi-asserted-by":"crossref","first-page":"6521","DOI":"10.1182\/blood-2011-05-351403","article-title":"Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"118","author":"Fo\u00e0","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.07.016_bib0011","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3324\/haematol.10822","article-title":"Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain","volume":"92","author":"Soverini","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2024.07.016_bib0012","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1182\/blood.2022016194","article-title":"The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis","volume":"140","author":"Ghobadi","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.07.016_bib0013","doi-asserted-by":"crossref","first-page":"5078","DOI":"10.1182\/bloodadvances.2020002945","article-title":"Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide","volume":"4","author":"Webster","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2024.07.016_bib0014","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators","volume":"18","author":"Gooley","year":"1999","journal-title":"Stat Med"},{"key":"10.1016\/j.jtct.2024.07.016_bib0015","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.jtct.2024.07.016_bib0016","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3324\/haematol.2014.116954","article-title":"Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia","volume":"100","author":"Brissot","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2024.07.016_bib0017","doi-asserted-by":"crossref","first-page":"7180","DOI":"10.1158\/1078-0432.CCR-06-1112","article-title":"Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure","volume":"12","author":"Luo","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtct.2024.07.016_bib0018","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1182\/blood-2007-02-073528","article-title":"Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study","volume":"110","author":"Ottmann","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.07.016_bib0019","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O'Hare","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtct.2024.07.016_bib0023","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1200\/JCO.20.02529","article-title":"Total body irradiation or chemotherapy conditioning in childhood ALL: a multinational, randomized, noninferiority phase III study","volume":"39","author":"Peters","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2024.07.016_bib0024","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3324\/haematol.2016.145631","article-title":"Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"102","author":"Giebel","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2024.07.016_bib0025","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13045-019-0790-x","article-title":"Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT","volume":"12","author":"Pavl\u016f","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jtct.2024.07.016_bib0026","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/bmt.2015.278","article-title":"Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT","volume":"51","author":"Cahu","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.07.016_bib0027","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1002\/cncr.30130","volume":"122","author":"Giebel","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2024.07.016_bib0028","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/leu.2012.352","article-title":"Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia","volume":"27","author":"Pfeifer","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2024.07.016_bib0029","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1136\/jclinpath-2022-208340","article-title":"Dasatinib-induced Crohn's-like colitis","volume":"76","author":"Grillo","year":"2023","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.jtct.2024.07.016_bib0030","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s11418-023-01715-9","article-title":"Ruscogenin ameliorates dasatinib-induced intestinal barrier dysfunction via ErbB4\/YAP and ROCK\/MLC pathways","volume":"77","author":"Huang","year":"2023","journal-title":"J Nat Med"},{"key":"10.1016\/j.jtct.2024.07.016_bib0031","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/S0140-6736(09)60237-3","article-title":"Graft-versus-host disease","volume":"373","author":"Ferrara","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2024.07.016_bib0032","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra1609337","article-title":"Acute graft-versus-host disease\u2014biologic process, prevention, and therapy","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2024.07.016_bib0033","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41375-019-0544-3","article-title":"Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT","volume":"34","author":"Shem-Tov","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2024.07.016_bib0034","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13045-021-01065-7","volume":"14","author":"Nagler","year":"2021","journal-title":"J Hematol Oncol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724005475?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724005475?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T03:39:21Z","timestamp":1767238761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636724005475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2666636724005475"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2024.07.016","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of the Type of Tyrosine Kinase Inhibitor (imatinib or dasatinib) Used Before allo-HCT on Outcome of Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia. A Study on Behalf of the Acute Leukemia Working Party of the EBMT","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2024.07.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}